Printed From:

1. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. Jama. 1994; 271: 840-4.
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98: 946-52.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983-8.
4. Camm J, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal (2010) 31, 2369–2429.
5. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006; 166: 719-28.
6. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J. 2007; 28: 2803-17.
7. Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs Today (Barc). 2006; 42: 75-86.
8. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart : comparison with amiodarone. Circulation. 1999; 100: 2276-81.
9. Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol. 2003; 91: 15D-26D.
10. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, Biollaz J. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007; 64: 785-91.
11. Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace. 2008; 10: 647-65.
12. Doggrell SA, Hancox JC. Dronedarone: an amiodarone analogue. Expert Opin Investig Drugs. 2004; 13: 415-26.
13. Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev. 2005; 23: 217-30.
14. Lalevee N, Nargeot J, Barrere-Lemaire S, Gautier P, Richard S. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J Cardiovasc Electrophysiol. 2003; 14: 885-90.
15. Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur J Pharmacol. 1995; 279: 25-32.
16. Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart. Br J Pharmacol. 1995; 116: 1949-56.
17. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357: 987-99.
18. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003; 24: 1481-7.
19. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360: 668-78.
20. Varro A, Takacs J, Nemeth M, Hala O, Virag L, Iost N, Balati B, Agoston M, Vereckei A, Pastor G, Delbruyere M, Gautier P, Nisato D, Papp JG. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. Br J Pharmacol. 2001; 133: 625-34.
21. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, Van Kempen L. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008; 156: 527 e1-9.
22. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358: 2678-87.
23. Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol. 2008; 19: 69-73.
24. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation. 1991; 84: 40-8.
25. Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009; 120: 1174-80.
26. Crijns H, Connolly SJ, Gaudin C, Page RL, Torp-Pedersen C, van Eickels M, Hohnloser SH. Effect of Dronedarone on Clinical Endpoints in Patients with AF and Coronary Heart Disease - Insights from the ATHENA Study. European Society of Cardiology 2009. Barcelona, 2009.
27. Lewalter T, Tebbenjohanns J, Wichter T, Antz M, Geller C, Seidl K-H, Gulba D, Röhrig FR, Willems S. Kommentar zu "ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation - executive summary". Kardiologe. 2008; 2: 181-205.
28. Ficha técnica de Multaq
29. Le Heuzy JY et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodaron in patients with persistent atrial fibrillation. The DIONYSOS study. J Cardiovasc Electrophysiol 2010: 21: 597-605.
30. Sahadevan J und Waldo AL. A perspective on DIONYSOS. J Cardiovasc Electrophysiol 2010
31. Wyse DG et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1825-1833
32. Kochiadakis GE et al. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation. Amiodarone vs. propafenone, both in low doses. Chest 2004; 125: 377-383.

Área para Profesionales